Sign in
Taking people in NetherlandsPhase 1

Tests MK-8294 alone in adults with advanced solid tumors

Tests MK-8294 alone in adults with advanced cancers of several kinds.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Amsterdam and Nijmegen, NetherlandsSee the 2 sites
Trial code
Registry title
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors
Status
Recruiting
Phase
Phase 1
People taking part
21 people, planned
Started
11 Jul 2025
Expected to end
1 Jul 2027
Type of study
Interventional
Record updated
28 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with certain advanced solid tumors, including endometrial, bladder, head and neck, esophageal, cervical and breast cancer. They would receive MK-8294 alone.

Age
18 years or older
Sex
All sexes can join
Disease stage
Advanced solid tumors (the record does not give more detail)

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in Netherlands

  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
  • Radboud universitair medisch centrum StichtingNijmegen, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests MK-8294 alone in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 May 2026